Epidemiology & Cancer Statistics Group, University of York, York, YO10 5DD, UK.
Department of Palliative Care, York Hospital, York, YO31 8HE, UK.
BMC Palliat Care. 2018 Feb 21;17(1):33. doi: 10.1186/s12904-018-0289-1.
Haematological malignancies (leukaemias, lymphomas and myeloma) are complex cancers that are relatively common, affect all ages and have divergent outcomes. Although the symptom burden of these diseases is comparable to other cancers, patients do not access specialist palliative care (SPC) services as often as those with other cancers. To determine the reasons for this, we asked SPC practitioners about their perspectives regarding the barriers and facilitators influencing haematology patient referrals.
We conducted a qualitative study, set within the United Kingdom's (UK's) Haematological Malignancy Research Network (HMRN: www.hmrn.org ), a population-based cohort in the North of England. In-depth, semi-structured interviews were conducted with 20 SPC doctors and nurses working in hospital, community and hospice settings between 2012 and 2014. Interviews were digitally audio-recorded, transcribed and analysed for thematic content using the 'Framework' method.
Study participants identified a range of barriers and facilitators influencing the referral of patients with haematological malignancies to SPC services. Barriers included: the characteristics and pathways of haematological malignancies; the close patient/haematology team relationship; lack of role clarity; late end of life discussions and SPC referrals; policy issues; and organisational issues. The main facilitators identified were: establishment of inter-disciplinary working patterns (co-working) and enhanced understanding of roles; timely discussions with patients and early SPC referral; access to information platforms able to support information sharing; and use of indicators to 'flag' patients' needs for SPC. Collaboration between haematology and SPC was perceived as beneficial and desirable, and was said to be increasing over time.
This is the first UK study to explore SPC practitioners' perceptions concerning haematology patient referrals. Numerous factors were found to influence the likelihood of referral, some of which related to the organisation and delivery of SPC services, so were amenable to change, and others relating to the complex and unique characteristics and pathways of haematological cancers. Further research is needed to assess the extent to which palliative care is provided by haematology doctors and nurses and other generalists and ways in which clinical uncertainty could be used as a trigger, rather than a barrier, to referral.
血液系统恶性肿瘤(白血病、淋巴瘤和骨髓瘤)是较为常见的复杂癌症,可影响所有年龄段人群,且具有不同的结局。尽管这些疾病的症状负担与其他癌症相当,但患者接受专科姑息治疗(SPC)服务的频率并不像其他癌症患者那样高。为了确定其中的原因,我们向 SPC 从业者询问了他们对影响血液学患者转介的障碍和促进因素的看法。
我们开展了一项定性研究,该研究隶属于英国血液恶性肿瘤研究网络(HMRN:www.hmrn.org),这是英格兰北部的一个基于人群的队列。2012 年至 2014 年期间,我们在医院、社区和临终关怀环境中对 20 名从事 SPC 工作的医生和护士进行了深入的半结构化访谈。访谈采用数字音频记录,使用“框架”方法对转录文本进行主题内容分析。
研究参与者确定了一系列影响将血液恶性肿瘤患者转介至 SPC 服务的障碍和促进因素。障碍包括:血液恶性肿瘤的特征和途径;患者/血液学团队之间的密切关系;角色不明确;临终讨论和 SPC 转介较晚;政策问题;以及组织问题。主要的促进因素包括:建立跨学科工作模式(合作)和增强对角色的理解;与患者及时进行讨论并尽早进行 SPC 转介;获得能够支持信息共享的信息平台;以及使用指标来“标记”患者对 SPC 的需求。血液学和 SPC 之间的合作被认为是有益和可取的,而且据说随着时间的推移正在增加。
这是英国第一项探讨 SPC 从业者对血液学患者转介看法的研究。研究发现,许多因素会影响转介的可能性,其中一些与 SPC 服务的组织和提供有关,因此是可以改变的,而另一些则与血液恶性肿瘤的复杂和独特特征和途径有关。需要进一步研究以评估血液学医生和护士以及其他通科医生提供姑息治疗的程度,以及如何将临床不确定性用作转介的触发因素而不是障碍。